The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Association of rash with improved outcomes by the addition of cetuximab (C) to second-line mitoxantrone plus prednisone (MP) for progressive mCRPC after docetaxel-based chemotherapy.
W. R. Berry
Honoraria - Amgen; Sanofi
M. T. Fleming
No relevant relationships to disclose
T. M. Beer
Research Funding - ImClone Systems
M. A. Kolodziej
No relevant relationships to disclose
S. Awasthi
No relevant relationships to disclose
T. E. Hutson
No relevant relationships to disclose
D. Martincic
No relevant relationships to disclose
Y. Wang
No relevant relationships to disclose
L. Asmar
No relevant relationships to disclose
G. Sonpavde
No relevant relationships to disclose